Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prostatic cancer marker PLXNA1 and application thereof

A prostate cancer and marker technology, applied in the field of cancer diagnosis, can solve the problem of lack of molecular typing markers in prostate cancer

Inactive Publication Date: 2017-07-21
SHANGHAI CHANGHAI HOSPITAL
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are many detection kits used in the world to judge the prognosis of prostate cancer patients, such as the commercialized Prolaris (46genes), Decipher (22genes), Oncotype DX (17genes), covering a total of 85 genes, while only Prolaris There is a common gene in Decipher, and neither has been verified in Chinese population samples, because it can be seen that prostate cancer still lacks ideal molecular typing markers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prostatic cancer marker PLXNA1 and application thereof
  • Prostatic cancer marker PLXNA1 and application thereof
  • Prostatic cancer marker PLXNA1 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Example 1 Expression of Cellular Level PLXNA1

[0055] (1.1) Effect of si-RNA-mediated knockdown of PLXNA1 on cell phenotype

[0056] The present invention detected the effect of si-RNA-mediated PLXNA1 knockdown on cell phenotype, and found that after si-RNA knockdown of PLXNA1 expression, the invasion ability of prostate cancer cells was significantly reduced ( figure 1 a) and migration ability ( figure 1 b). In the different types of prostate cancer cell lines detected (including C4-2, PC-3, LNCaP), knocking down the expression of PLXNA1 by si-RNA significantly reduced the ability of cell proliferation, invasion and metastasis ( figure 1 c-e).

[0057] The prostate cancer cell lines involved in the experiment were all derived from American ATCC cell lines, and the cells were cultured in RPMI 1640+10% fetal bovine serum, placed in a 5% CO2 incubator at 37°C.

[0058] Before the invasion and migration experiments, the cells were divided into 6-well plates, and 100nM...

Embodiment 2

[0065] Example 2 Tumor-bearing nude mouse model to evaluate the effect of PLXNA1 knockdown on cell proliferation.

[0066] (2.1) Effect of shRNA-mediated PLXNA1 knockdown on tumor volume and weight

[0067] The effect of PLXNA1 knockdown on cell growth was assessed in vivo using a tumor-bearing nude mouse model. In nude mice with shRNA-mediated PLXNA1 stably knocked down cells, tumor volume and weight were significantly lower than those in control mice ( Figure 4 a).

[0068] (2.2) Effect of PLXNA1 overexpression on tumor growth in tumor-bearing nude mice

[0069] The present invention subcutaneously injects tumor cells into the nude mice of the control group or the experimental group by subcutaneously bearing tumors, observes the proliferation of tumor cells, and finds that the overexpression of PLXNA1 significantly enhances the growth of tumors in the nude mice bearing tumors.

[0070] Specifically, tumor-bearing mice with PLXNA1-overexpressed prostate cancer cell lines ...

Embodiment 3

[0089] Example 3 The clinical significance of PLXNA1 in the development and prognosis of prostate cancer

[0090] (3.1) Expression of PLXNA1 in metastatic prostate cancer

[0091]In order to evaluate the clinical significance of PLXNA1 in the occurrence and development of human prostate cancer, the present invention first researched and explored the possible relationship between the expression of PLXNA1 and the degree of malignancy of the disease. The data in the existing clinical database were analyzed, and it was found that the expression level of PLXNA1 was significantly higher in metastatic prostate cancer than in non-metastatic prostate cancer ( Figure 5 a-d), in prostate cancer was significantly higher than the corresponding normal control tissue ( Figure 5 e).

[0092] (3.2) Correlation between PLXNA1 expression and prognosis

[0093] (3.2.1) Correlation of PLXNA1 with PSA and clinical stage

[0094] In the present invention, the PSA (Prostate specific antigen) of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of PLXNA1 (PlexinA1) as a marker for prediction of prostatic cancer generation, development and prognosis and distinguishment of prostatic cancer with high progressive malignant degree. By detecting the PLXNA1 DNA copy number change, the expression level of mRNA and its encoding protein, diagnosis and prognosis can be carried out on prostatic cancer, the PLXNA1 has the characteristics of high accuracy, high specificity and high sensitivity. The invention also discloses application of the PLXNA1 as a therapeutic target of prostatic cancer. The invention also discloses a kit for diagnosing and predicting prostatic cancer, the kit is convenient for use, and can be used for diagnosis and prediction of prostatic cancer.

Description

technical field [0001] The invention belongs to the field of cancer diagnosis, and specifically relates to PLXNA1 as a marker for distinguishing advanced malignant prostate cancer and its application, and also relates to a corresponding diagnostic kit. Background technique [0002] Prostate cancer (PCa) is a malignant tumor that seriously threatens men's health. Its morbidity and mortality peak at around 70 years old, accounting for the second highest incidence of cancer and the sixth highest mortality in the world. In 2016, there were approximately 180,890 new cases and 26,120 deaths in the United States. However, prostate cancer has significant racial disparities. In the United States alone, the incidence of prostate cancer in African-Americans is twice that of Caucasians; in addition, its incidence in Asia is also significantly lower than in Western countries. Therefore, intra-ethnic genomic analysis of prostate cancer is urgently needed. [0003] Prostate cancer has s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68G01N33/574G01N33/68A61K38/17A61K45/00A61P35/00
CPCA61K38/177A61K45/00G01N33/57434G01N33/57484G01N33/68C12Q1/6886C12Q2600/118C12Q2600/112C12Q2600/158G01N2800/56G01N2800/52C12N15/113C12N2310/14C12N2310/531G01N33/5011
Inventor 孙颖浩任善成朱亚生施晓磊
Owner SHANGHAI CHANGHAI HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com